Tachykinin receptors as therapeutic targets in stress-related disorders

Current Pharmaceutical Design

Volumn 15, Issue 14, 2009, Pages 1647-1674

  Ebner, Karl ^a   Sartori, Simone B ^a   Singewald, Nicolas ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Antidepressant; Anxiety; Anxiolytic; Depression; Multi target approach; Neurokinin; NK2 receptor; NK3 receptor; NKA; NKB; NKI receptor; Panic; Schizophrenia; Stress; Substance P; Tachykinin

Indexed keywords

2 [1 IMINO 2 (2 METHOXYPHENYL)ETHYL] 7,7 DIPHENYLPERHYDROISOINDOL 4 ONE; 3 (2 METHOXY 5 TRIFLUOROMETHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; 3 (2 METHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; 3 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXY] 2 PHENYLPIPERIDINE; ANTIDEPRESSANT AGENT; APREPITANT; BENZODIAZEPINE DERIVATIVE; CASOPITANT; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; GR 205071; GW 823296; HALOPERIDOL; L 759274; L 822429; NEUROLEPTIC AGENT; NOLPITANTIUM; ORVEPITANT; OSANETANT; PAROXETINE; PLACEBO; R 673; SAREDUTANT; SEROTONIN UPTAKE INHIBITOR; SR 146977; SSR 146977; TACHYKININ RECEPTOR; TACHYKININ RECEPTOR ANTAGONIST; TALNETANT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VESTIPITANT; VOFOPITANT; TACHYKININ;

ADD ON THERAPY; ANIMAL BEHAVIOR; ANXIETY DISORDER; BINDING SITE; BRAIN REGION; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEPRESSION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG TARGETING; EVOKED RESPONSE; GENERALIZED ANXIETY DISORDER; HUMAN; INTERNEURON; MAJOR DEPRESSION; MENTAL STRESS; NAUSEA; NEUROMODULATION; NEUROPATHOLOGY; NEUROTRANSMISSION; NONHUMAN; PANIC; PATIENT COMPLIANCE; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; PSYCHOSOCIAL DISORDER; RECEPTOR AFFINITY; RECEPTOR DENSITY; REVIEW; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SINGLE DRUG DOSE; TRANQUILIZING ACTIVITY; UNSPECIFIED SIDE EFFECT; ANIMAL; DISEASE MODEL; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG SCREENING; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; ANXIETY DISORDERS; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; HUMANS; RECEPTORS, TACHYKININ; SCHIZOPHRENIA; TACHYKININS;

EID: 67650569457     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209788168074     Document Type: Review

References (336)

1. Pennefather JN, Lecci A, Candenas ML, Patak E, Pinto FM, Maggi CA. Tachykinins and tachykinin receptors: A growing family. Life Sci 2004; 74: 1445-63.
2. Saria A. The tachykinin NK1 receptor in the brain: Pharmacology and putative functions. Eur J Pharmacol 1999; 375: 51-60.
3. Otsuka M, Yoshioka K. Neurotransmitter functions of mammalian tachykinins. Physiol Rev 1993; 73: 229-308.
4. Duffy RA, Hedrick JA, Randolph G, Morgan CA, Cohen-Williams ME, Vassileva G, et al. Centrally administered hemokinin-1 (HK-1), a neurokinin NK1 receptor agonist, produces substance P-like behavioral effects in mice and gerbils. Neuropharmacology 2003; 45: 242-50.
5. Page NM. New challenges in the study of the mammalian tachykinins. Peptides 2005; 26: 1356-68.
6. Patacchini R, Lecci A, Holzer P, Maggi CA. Newly discovered tachykinins raise new questions about their peripheral roles and the tachykinin nomenclature. Trends Pharmacol Sci 2004; 25: 1-3.
7. Krause JE, Chirgwin JM, Carter MS, Xu ZS, Hershey AD. Three rat preprotachykinin mRNAs encode the neuropeptides substance P and neurokinin A. Proc Natl Acad Sci USA 1987; 84: 881-5.
8. Harmar AJ, Hyde V, Chapman K. Identification and cDNA sequence of delta-preprotachykinin, a fourth splicing variant of the rat substance P precursor. FEBS Lett 1990; 275: 22-4.
9. Nawa H, Hirose T, Takashima H, Inayama S, Nakanishi S. Nucleotide sequences of cloned cDNAs for two types of bovine brain substance P precursor. Nature 1983; 306: 32-6.
10. Nawa H, Kotani H, Nakanishi S. Tissue-specific generation of two preprotachykinin mRNAs from one gene by alternative RNA splicing. Nature 1984; 312: 729-34.
11. Severini C, Improta G, Falconieri-Erspamer G, Salvadori S, Erspamer V. The tachykinin peptide family. Pharmacol Rev 2002; 54: 285-322.
12. Carter MS, Krause JE. Structure, expression, and some regulatory mechanisms of the rat preprotachykinin gene encoding substance P, neurokinin A, neuropeptide K, and neuropeptide gamma. J Neurosci 1990; 10: 2203-14.
13. Kotani H, Hoshimaru M, Nawa H, Nakanishi S. Structure and gene organization of bovine neuromedin K precursor. Proc Natl Acad Sci USA 1986; 83: 7074-8.
14. Page NM. Hemokinins and endokinins. Cell Mol Life Sci 2004; 61: 1652-63.
15. Zhang Y, Lu L, Furlonger C, Wu GE, Paige CJ. Hemokinin is a hematopoietic-specific tachykinin that regulates B lymphopoiesis. Nat Immunol 2000; 1: 392-7.
16. Hökfelt T, Kuteeva E, Stanic D, Ljungdahl A. In: Holzer P Ed, The histochemistry of tachykinin systems in the brain. Berlin-Heidelberg: Springer 2004; pp. 63-120.
17. Nakaya Y, Kaneko T, Shigemoto R, Nakanishi S, Mizuno N. Immunohistochemical localization of substance P receptor in the central nervous system of the adult rat. J Comp Neurol 1994; 347: 249-74.
18. Ribeiro-da-Silva A, Hökfelt T. Neuroanatomical localisation of Substance P in the CNS and sensory neurons. Neuropeptides 2000; 34: 256-71.
19. Shults CW, Quirion R, Chronwall B, Chase TN, O'Donohue TL. A comparison of the anatomical distribution of substance P and substance P receptors in the rat central nervous system. Peptides 1984; 5: 1097-128.
20. Roberts GW, Woodhams PL, Polak JM, Crow TJ. Distribution of neuropeptides in the limbic system of the rat: The amygdaloid complex. Neuroscience 1982; 7: 99-131.
21. Woodhams PL, Roberts GW, Polak JM, Crow TJ. Distribution of neuropeptides in the limbic system of the rat: The bed nucleus of the stria terminalis, septum and preoptic area. Neuroscience 1983; 8: 677-703.
22. Hökfelt T, Meister B, Melander T, Everitt B. Coexistence of classical transmitters and peptides with special reference to the arcuate nucleus - median eminence complex. Adv Biochem Psychopharmacol 1987; 43: 21-34.
23. Merighi A. Costorage and coexistence of neuropeptides in the mammalian CNS. Prog Neurobiol 2002; 66: 161-90.
24. Zupanc GK. Peptidergic transmission: From morphological correlates to functional implications. Micron 1996; 27: 35-91.
25. Chawla MK, Gutierrez GM, Young WS, 3rd, McMullen NT, Rance NE. Localization of neurons expressing substance P and neurokinin B gene transcripts in the human hypothalamus and basal forebrain. J Comp Neurol 1997; 384: 429-42.
26. Covenas R, Martin F, Belda M, Smith V, Salinas P, Rivada E, et al. Mapping of neurokinin-like immunoreactivity in the human brainstem. BMC Neurosci 2003; 4: 3.
27. Del Fiacco M, Levanti MC, Dessi ML, Zucca G. The human hippocampal formation and parahippocampal gyrus: Localization of substance P-like immunoreactivity in newborn and adult postmortem tissue. Neuroscience 1987; 21: 141-50.
28. Mai JK, Stephens PH, Hopf A, Cuello AC. Substance P in the human brain. Neuroscience 1986; 17: 709-39.
29. Sutoo D, Yabe K, Akiyama K. Quantitative imaging of substance P in the human brain using a brain mapping analyzer. Neurosci Res 1999; 35: 339-46.
30. Hökfelt T, Meyerson B, Nilsson G, Pernow B, Sachs C. Immunohistochemical evidence for substance P-containing nerve endings in the human cortex. Brain Res 1976; 104: 181-6.
31. Hurd YL, Keller E, Sotonyi P, Sedvall G. Preprotachykinin-A mRNA expression in the human and monkey brain: An in situ hybridization study. J Comp Neurol 1999; 411: 56-72.
32. Charara A, Parent A. Chemoarchitecture of the primate dorsal raphe nucleus. J Chem Neuroanat 1998; 15: 111-27.
33. Ma QP, Bleasdale C. Modulation of brain stem monoamines and gamma-aminobutyric acid by NK1 receptors in rats. Neuroreport 2002; 13: 1809-12.
34. Sergeyev V, Hökfelt T, Hurd Y. Serotonin and substance P co-exist in dorsal raphe neurons of the human brain. Neuroreport 1999; 10: 3967-70.
35. Arai H, Emson PC. Regional distribution of neuropeptide K and other tachykinins (neurokinin A, neurokinin B and substance P) in rat central nervous system. Brain Res 1986; 399: 240-9.
36. Lindefors N, Brodin E, Theodorsson-Norheim E, Ungerstedt U. Regional distribution and in vivo release of tachykinin-like immunoreactivities in rat brain: Evidence for regional differences in relative proportions of tachykinins. Regul Pept 1985; 10: 217-30.
37. Shults CW, Yajima H, Gullner HG, Chase TN, O'Donohue TL. Demonstration and distribution of kassinin-like material (substance K) in the rat central nervous system. J Neurochem 1985; 45: 552-8.
38. Lucas LR, Hurley DL, Krause JE, Harlan RE. Localization of the tachykinin neurokinin B precursor peptide in rat brain by immunocytochemistry and in situ hybridization. Neuroscience 1992; 51: 317-45.
39. Marksteiner J, Sperk G, Krause JE. Distribution of neurons expressing neurokinin B in the rat brain: Immunohistochemistry and in situ hybridization. J Comp Neurol 1992; 317: 341-56.
40. Merchenthaler I, Maderdrut JL, O'Harte F, Conlon JM. Localization of neurokinin B in the central nervous system of the rat. Peptides 1992; 13: 815-29.
41. Warden MK, Young WSr. Distribution of cells containing mRNAs encoding substance P and neurokinin B in the rat central nervous system. J Comp Neurol 1988; 272: 90-113.
42. Roberts GW, Woodhams PL, Polak JM, Crow TJ. Distribution of neuropeptides in the limbic system of the rat: The hippocampus. Neuroscience 1984; 11: 35-77.
43. Duarte CR, Schutz B, Zimmer A. Incongruent pattern of neurokinin B expression in rat and mouse brains. Cell Tissue Res 2006; 323: 43-51
44. Khawaja AM, Rogers DF. Tachykinins: Receptor to effector. Int J Biochem Cell Biol 1996; 28: 721-38.
45. Nakajima Y, Tsuchida K, Negishi M, Ito S, Nakanishi S. Direct linkage of three tachykinin receptors to stimulation of both phosphatidylinositol hydrolysis and cyclic AMP cascades in transfected Chinese hamster ovary cells. J Biol Chem 1992; 267: 2437-42.
46. Maggi CA. The mammalian tachykinin receptors. Gen Pharmacol 1995; 26: 911-44.
47. Regoli D, Boudon A, Fauchere JL. Receptors and antagonists for substance P and related peptides. Pharmacol Rev 1994; 46: 551-99.
48. Maggi CA, Schwartz TW. The dual nature of the tachykinin NK1 receptor. Trends Pharmacol Sci 1997; 18: 351-5.
49. Beaujouan JC, Saffroy M, Torrens Y, Sagan S, Glowinski J. Pharmacological characterization of tachykinin septide-sensitive binding sites in the rat submaxillary gland. Peptides 1999; 20: 1347-52.
50. Fong TM, Yu H, Strader CD. Molecular basis for the species selectivity of the neurokinin-1 receptor antagonists CP-96,345 and RP67580. J Biol Chem 1992; 267: 25668-71.
51. Sachais BS, Snider RM, Lowe JAr, Krause JE. Molecular basis for the species selectivity of the substance P antagonist CP-96,345. J Biol Chem 1993; 268: 2319-23.
52. Beresford IJ, Birch PJ, Hagan RM, Ireland SJ. Investigation into species variants in tachykinin NK1 receptors by use of the non-peptide antagonist, CP-96,345. Br J Pharmacol 1991; 104: 292-3.
53. Gether U, Johansen TE, Snider RM, Lowe JAr, Nakanishi S, Schwartz TW. Different binding epitopes on the NK1 receptor for substance P and non-peptide antagonist. Nature 1993; 362: 345-8.
54. Saffroy M, Torrens Y, Glowinski J, Beaujouan JC. Autoradiographic distribution of tachykinin NK2 binding sites in the rat brain: comparison with NK1 and NK3 binding sites. Neuroscience 2003; 116: 761-73.
55. Ding YQ, Shigemoto R, Takada M, Ohishi H, Nakanishi S, Mizuno N. Localization of the neuromedin K receptor (NK3) in the central nervous system of the rat. J Comp Neurol 1996; 364: 290-310.
56. Yip J, Chahl LA. Localization of NK1 and NK3 receptors in guinea-pig brain. Regul Pept 2001; 98: 55-62.
57. Ebner K, Singewald GM, Whittle N, Ferraguti F, Singewald N. Neurokinin 1 receptor antagonism promotes active stress coping via enhanced septal 5-HT transmission. Neuropsychopharmacology 2008; 33: 1929-41.
58. Mileusnic D, Lee JM, Magnuson DJ, Hejna MJ, Krause JE, Lorens JB, et al. Neurokinin-3 receptor distribution in rat and human brain: An immunohistochemical study. Neuroscience 1999; 89: 1269-90.
59. Tooney PA, Au GG, Chahl LA. Tachykinin NK1 and NK3 receptors in the prefrontal cortex of the human brain. Clin Exp Pharmacol Physiol 2000; 27: 947-9.
60. Langlois X, Wintmolders C, te Riele P, Leysen JE, Jurzak M. Detailed distribution of Neurokinin 3 receptors in the rat, guinea pig and gerbil brain: A comparative autoradiographic study. Neuropharmacology 2001; 40: 242-53.
61. Rigby M, O'Donnell R, Rupniak NM. Species differences in tachykinin receptor distribution: Further evidence that the substance P (NK1) receptor predominates in human brain. J Comp Neurol 2005; 490: 335-53
62. Beaujouan JC, Torrens Y, Saffroy M, Kemel ML, Glowinski J. A 25 year adventure in the field of tachykinins. Peptides 2004; 25: 339-57.
63. Herkenham M. Mismatches between neurotransmitter and receptor localizations in brain: Observations and implications. Neuroscience 1987; 23: 1-38.
64. Landgraf R, Neumann ID. Vasopressin and oxytocin release within the brain: A dynamic concept of multiple and variable modes of neuropeptide communication. Front Neuroendocrinol 2004; 25: 150-76.
65. Fuxe K, Agnati LF. Volume Transmission in the Brain: Novel Mechanisms for Neural Transmission. New York: Raven Press 1991.
66. Malcangio M, Bowery NG. Peptide autoreceptors: Does an autoreceptor for substance P exist? Trends Pharmacol Sci 1999; 20: 405-7.
67. Malcangio M, Bowery NG. Effect of the tachykinin NK1 receptor antagonists, RP 67580 and SR 140333, on electrically-evoked substance P release from rat spinal cord. Br J Pharmacol 1994; 113: 635-41.
68. Singewald N, Chicchi GG, Thurner CC, Tsao KL, Spetea M, Schmidhammer H, et al. Modulation of basal and stress-induced amygdaloid substance P release by the potent and selective NK1 receptor antagonist L-822429. J Neurochem 2008; 106: 2476-88.
69. Barbaresi P. Immunocytochemical localization of substance P receptor in rat periaqueductal gray matter: A light and electron microscopic study. J Comp Neurol 1998; 398: 473-90.
70. Jakab RL, Goldman-Rakic P. Presynaptic and postsynaptic subcellular localization of substance P receptor immunoreactivity in the neostriatum of the rat and rhesus monkey (Macaca mulatta). J Comp Neurol 1996; 369: 125-36.
71. Levesque M, Parent R, Parent A. Cellular and subcellular localization of neurokinin-1 and neurokinin-3 receptors in primate globus pallidus. Eur J Neurosci 2006; 23: 2760-72.
72. Pickel VM, Douglas J, Chan J, Gamp PD, Bunnett NW. Neurokinin 1 receptor distribution in cholinergic neurons and targets of substance P terminals in the rat nucleus accumbens. J Comp Neurol 2000; 423: 500-11.
73. Stacey AE, Woodhall GL, Jones RS. Activation of neurokinin-1 receptors promotes GABA release at synapses in the rat entorhinal cortex. Neuroscience 2002; 115: 575-86.
74. Wolansky T, Pagliardini S, Greer JJ, Dickson CT. Immunohistochemical characterization of substance P receptor (NK1R)-expressing interneurons in the entorhinal cortex. J Comp Neurol 2007; 502: 427-41.
75. Stacey AE, Woodhall GL, Jones RS. Neurokinin-receptor-mediated depolarization of cortical neurons elicits an increase in glutamate release at excitatory synapses. Eur J Neurosci 2002; 16: 1896-906.
76. Simmons MA, Sobotka-Briner CD, Medd AM. Localization and function of NK3 subtype tachykinin receptors of layer V pyramidal neurons of the guinea-pig medial prefrontal cortex. Neuroscience 2008; 156: 987-94
77. Rekling JC. NK-3 receptor activation depolarizes and induces an after-depolarization in pyramidal neurons in gerbil cingulate cortex. Brain Res Bull 2004; 63: 85-90.
78. Kouznetsova M, Nistri A. Modulation by substance P of synaptic transmission in the mouse hippocampal slice. Eur J Neurosci 1998; 10: 3076-84.
79. Maubach KA, Martin K, Smith DW, Hewson L, Frankshun RA, Harrison T, et al. Substance P stimulates inhibitory synaptic transmission in the guinea pig basolateral amygdala in vitro. Neuropharmacology 2001; 40: 806-17.
80. Ogier R, Raggenbass M. Action of tachykinins in the rat hippocampus: modulation of inhibitory synaptic transmission. Eur J Neurosci 2003; 17: 2639-47.
81. Levita L, Mania I, Rainnie DG. Subtypes of substance P receptor immunoreactive interneurons in the rat basolateral amygdala. Brain Res 2003; 981: 41-51.
82. Marchetti C, Nistri A. Neuronal bursting induced by NK3 receptor activation in the neonatal rat spinal cord in vitro. J Neurophysiol 2001; 86: 2939-50.
83. Preston Z, Richardson PJ, Pinnock RD, Lee K. NK-3 receptors are expressed on mouse striatal gamma-aminobutyric acid-ergic interneurones and evoke [(3)H] gamma-aminobutyric acid release. Neurosci Lett 2000; 284: 89-92.
84. Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006; 7: 137-51.
85. Mann JJ. The medical management of depression. N Engl J Med 2005; 353: 1819-34.
86. Gobbi G, Blier P. Effect of neurokinin-1 receptor antagonists on serotoninergic, noradrenergic and hippocampal neurons: Comparison with antidepressant drugs. Peptides 2005; 26: 1383-93.
87. Blier P, de Montigny C. Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders. Neuropsychopharmacology 1999; 21: 91S-98S.
88. Gobbi G, Cassano T, Radja F, Morgese MG, Cuomo V, Santarelli L, et al. Neurokinin 1 receptor antagonism requires norepinephrine to increase serotonin function. Eur Neuropsychopharmacol 2007; 17: 328-38.
89. Sheehan TP, Chambers RA, Russell DS. Regulation of affect by the lateral septum: Implications for neuropsychiatry. Brain Res Brain Res Rev 2004; 46: 71-117.
90. Bert L, Rodier D, Bougault I, Allouard N, Le-Fur G, Soubrie P, et al. Permissive role of neurokinin NK3 receptors in NK1 receptor-mediated activation of the locus coeruleus revealed by SR 142801. Synapse 2002; 43: 62-9.
91. Cheeseman HJ, Pinnock RD, Henderson G. Substance P excitation of rat locus coeruleus neurones. Eur J Pharmacol 1983; 94: 93-9.
92. Guyenet PG, Aghajanian GK. Excitation of neurons in the nucleus locus coeruleus by substance P and related peptides. Brain Res 1977; 136: 178-84.
93. Jung M, Michaud JC, Steinberg R, Barnouin MC, Hayar A, Mons G, et al. Electrophysiological, behavioural and biochemical evidence for activation of brain noradrenergic systems following neurokinin NK3 receptor stimulation. Neuroscience 1996; 74: 403-14.
94. McLean S, Ganong A, Seymour PA, Snider RM, Desai MC, Rosen T, et al. Pharmacology of CP-99,994; a nonpeptide antagonist of the tachykinin neurokinin-1 receptor. J Pharmacol Exp Ther 1993; 267: 472-9.
95. Millan MJ, Lejeune F, De Nanteuil G, Gobert A. Selective blockade of neurokinin (NK1) receptors facilitates the activity of adrenergic pathways projecting to frontal cortex and dorsal hippocampus in rats. J Neurochem 2001; 76: 1949-54.
96. Ebner K, Singewald N. Stress-induced release of substance P in the locus coeruleus modulates cortical noradrenaline release. Naunyn Schmiedebergs Arch Pharmacol 2007; 376: 73-82.
97. Fisher AS, Stewart RJ, Yan T, Hunt SP, Stanford SC. Disruption of noradrenergic transmission and the behavioural response to a novel environment in NK1R-/- mice. Eur J Neurosci 2007; 25: 1195-204.
98. Herpfer I, Hunt SP, Stanford SC. A comparison of neurokinin 1 receptor knock-out (NK1-/-) and wildtype mice: Exploratory behaviour and extracellular noradrenaline concentration in the cerebral cortex of anaesthetised subjects. Neuropharmacology 2005; 48: 706-19.
99. Ebner K, Rupniak NM, Saria A, Singewald N. Substance P in the medial amygdala: Emotional stress-sensitive release and modulation of anxiety-related behavior in rats. Proc Natl Acad Sci USA 2004; 101: 4280-5.
100. Hökfelt T, Broberger C, Xu ZQ, Sergeyev V, Ubink R, Diez M. Neuropeptides - an overview. Neuropharmacology 2000; 39: 1337-56.
101. Sarter M, Bruno JP, Parikh V. Abnormal neurotransmitter release underlying behavioral and cognitive disorders: Toward concepts of dynamic and function-specific dysregulation. Neuropsychopharmacology 2007; 32: 1452-61.
102. Renoldi G, Invernizzi RW. Blockade of tachykinin NK1 receptors attenuates stress-induced rise of extracellular noradrenaline and dopamine in the rat and gerbil medial prefrontal cortex. J Neurosci Res 2006; 84: 961-8.
103. Spooren W, Riemer C,TMeltzer H. Opinion: NK3 receptor antagonists: the next generation of antipsychotics? Nat Rev Drug Discov 2005; 4: 967-75.
104. Marco N, Thirion A, Mons G, Bougault I, Le Fur G, Soubrie P, et al. Activation of dopaminergic and cholinergic neurotransmission by tachykinin NK3 receptor stimulation: An in vivo microdialysis approach in guinea pig. Neuropeptides 1998; 32: 481-8.
105. Keegan KD, Woodruff GN, Pinnock RD. The selective NK3 receptor agonist senktide excites a subpopulation of dopamine-sensitive neurones in the rat substantia nigra pars compacta in vitro. Br J Pharmacol 1992; 105: 3-5.
106. Nalivaiko E, Michaud JC, Soubrie P, Le Fur G, Feltz P. Tachykinin neurokinin-1 and neurokinin-3 receptor-mediated responses in guinea-pig substantia nigra: An in vitro electrophysiological study. Neuroscience 1997; 78: 745-57.
107. Seabrook GR, Bowery BJ, Hill RG. Pharmacology of tachykinin receptors on neurones in the ventral tegmental area of rat brain slices. Eur J Pharmacol 1995; 273: 113-9.
108. Dawson LA, Cato KJ, Scott C, Watson JM, Wood MD, Foxton R, et al. In vitro and in vivo characterization of the non-peptide NK3 receptor antagonist SB-223412 (talnetant): Potential therapeutic utility in the treatment of schizophrenia. Neuropsychopharmacology 2008; 33: 1642-52.
109. de la Flor R, Dawson LA. Augmentation of antipsychotic-induced neurochemical changes by the NK(3) receptor antagonist talnetant (SB-223412). Neuropharmacology 2009; 56: 342-9.
110. Lejeune F, Gobert A, Millan MJ. The selective neurokinin (NK)(1) antagonist, GR205,171, stereospecifically enhances mesocortical dopaminergic transmission in the rat: A combined dialysis and electrophysiological study. Brain Res 2002; 935: 134-9.
111. Deutch AY, Maggio JE, Bannon MJ, Kalivas PW, Tam SY, Goldstein M, et al. Substance K and substance P differentially modulate mesolimbic and mesocortical systems. Peptides 1985; 6(Suppl 2): 113-22.
112. Reid MS, Herrera-Marschitz M, Ungerstedt U. Effects of intranigral substance P and neurokinin A injections on extracellular dopamine levels measured with microdialysis in the striatum and frontoparietal cortex of rats. J Neurochem 1991; 57: 970-4.
113. Hutson PH, Patel S, Jay MT, Barton CL. Stress-induced increase of cortical dopamine metabolism: Attenuation by a tachykinin NK1 receptor antagonist. Eur J Pharmacol 2004; 484: 57-64.
114. Esch T, Stefano GB, Fricchione GL, Benson H. The role of stress in neurodegenerative diseases and mental disorders. Neuro Endocrinol Lett 2002; 23: 199-208.
115. Kendler KS, Karkowski LM, Prescott CA. Causal relationship between stressful life events and the onset of major depression. Am J Psychiatry 1999; 156: 837-41.
116. Carrasco GA, Van de Kar LD. Neuroendocrine pharmacology of stress. Eur J Pharmacol 2003; 463: 235-72.
117. de Kloet ER, Joels M, Holsboer F. Stress and the brain: From adaptation to disease. Nat Rev Neurosci 2005; 6: 463-75.
118. McEwen BS. Physiology and neurobiology of stress and adaptation: Central role of the brain. Physiol Rev 2007; 87: 873-904.
119. Cryan JF, Slattery DA. Animal models of mood disorders: Recent developments. Curr Opin Psychiatry 2007; 20: 1-7.
120. Matthews K, Christmas D, Swan J, Sorrell E. Animal models of depression: navigating through the clinical fog. Neurosci Biobehav Rev 2005; 29: 503-13.
121. Nestler EJ, Gould E, Manji H, Buncan M, Duman RS, Greshenfeld HK, et al. Preclinical models: Status of basic research in depression. Biol Psychiatry 2002; 52: 503-28.
122. Willner P, Mitchell PJ. The validity of animal models of predisposition to depression. Behav Pharmacol 2002; 13: 169-88.
123. Culman J, Klee S, Ohlendorf C, Unger T. Effect of tachykinin receptor inhibition in the brain on cardiovascular and behavioral responses to stress. J Pharmacol Exp Ther 1997; 280: 238-46.
124. Unger T, Carolus S, Demmert G, Ganten D, Lang RE, Maser-Gluth C, et al. Substance P induces a cardiovascular defense reaction in the rat: pharmacological characterization. Circ Res 1988; 63: 812-20.
125. Mello DM, Marcinichen DR, Madruga D, Branco R, Paschoalini MA, De Lima TC. Involvement of NK1 receptors in metabolic stress markers after the central administration of substance P. Behav Brain Res 2007; 181: 232-8.
126. Kakol-Palm D, Brusberg M, Sand E, Larsson H, Martinez V, Johansson A, et al. Role of tachykinin NK1 and NK2 receptors in colonic sensitivity and stress-induced defecation in gerbils. Eur J Pharmacol 2008; 582: 123-31.
127. Rupniak NM, Carlson EJ, Webb JK, Harrison T, Porsolt RD, Roux S, et al. Comparison of the phenotype of NK1R-/- mice with pharmacological blockade of the substance P (NK1) receptor in assays for antidepressant and anxiolytic drugs. Behav Pharmacol 2001; 12: 497-508.
128. Santarelli L, Gobbi G, Debs PC, Sibille ET, Blier P, Hen R, et al. Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function. Proc Natl Acad Sci USA 2001; 98: 1912-7.
129. Jessop DS, Renshaw D, Larsen PJ, Chowdrey HS, Harbuz MS. Substance P is involved in terminating the hypothalamo- pituitary-adrenal axis response to acute stress through centrally located neurokinin-1 receptors. Stress 2000; 3: 209-20.
130. Nussdorfer GG, Malendowicz LK. Role of tachykinins in the regulation of the hypothalamo-pituitary-adrenal axis. Peptides 1998; 19: 949-68.
131. McCutcheon JE, Fisher AS, Guzdar E, Wood SA, Lightman SL, Hunt SP. Genetic background influences the behavioural and molecular consequences of neurokinin-1 receptor knockout. Eur J Neurosci 2008; 27: 683-90.
132. Ebner K, Singewald N. The role of substance P in stress and anxiety responses. Amino Acids 2006; 31: 251-72.
133. Herpfer I, Lieb K. Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential. CNS Drugs 2005; 19: 275-93.
134. Mantyh PW, Allen CJ, Ghilardi JR, Rogers SD, Mantyh CR, Liu H, et al. Rapid endocytosis of a G protein-coupled receptor: Substance P evoked internalization of its receptor in the rat striatum in vivo. Proc Natl Acad Sci USA 1995; 92: 2622-6.
135. Hwang BH, Katner J, Iyengar S. Corticotropin-releasing factor mRNA and substance P receptor binding in the paraventricular hypothalamic nucleus, central nucleus of the amygdala, and locus coeruleus of Sprague-Dawley rats following restraint-induced stress. J Mol Neurosci 2005; 25: 239-50.
136. Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998; 281: 1640-5.
137. Smith DW, Hewson L, Fuller P, Williams AR, Wheeldon A, Rupniak NM. The substance P antagonist L-760,735 inhibits stress-induced NK1 receptor internalisation in the basolateral amygdala. Brain Res 1999; 848: 90-5.
138. Steinberg R, Alonso R, Griebel G, Bert L, Jung M, Oury-Donat F, et al. Selective blockade of neurokinin-2 receptors produces antidepressant-like effects associated with reduced corticotropin-releasing factor function. J Pharmacol Exp Ther 2001; 299: 449-58.
139. Steinberg R, Alonso R, Rouquier L, Desvignes C, Michaud JC, Cudennec A, et al. SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl) phenyl]acetyl]-2-(3,4-dichloro phenyl)-2-morpholinyl] ethyl]-4- piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin 1 receptor: II. Neurochemical and behavioral characterization. J Pharmacol Exp Ther 2002; 303: 1180-8.
140. Takayama H, Ota Z, Ogawa N. Effect of immobilization stress on neuropeptides and their receptors in rat central nervous system. Regul Pept 1986; 15: 239-48.
141. Boyce S, Smith D, Carlson E, Hewson L, Rigby M, O'Donnell R, et al. Intra-amygdala injection of the substance P antagonist L-760735 inhibits neonatal vocalisations in guinea-pigs. Neuropharmacology 2001; 41: 130-7.
142. de Lange RP, Wiegant VM, Stam R. Altered neuropeptide Y and neurokinin messenger RNA expression and receptor binding in stress-sensitised rats. Brain Res 2008; 1212: 35-47.
143. Duric V, McCarson KE. Hippocampal neurokinin-1 receptor and brain-derived neurotrophic factor gene expression is decreased in rat models of pain and stress. Neuroscience 2005; 133: 999-1006.
144. Duric V, McCarson KE. Effects of analgesic or antidepressant drugs on pain- or stress-evoked hippocampal and spinal neurokinin-1 receptor and brain-derived neurotrophic factor gene expression in the rat. J Pharmacol Exp Ther 2006; 319: 1235-43.
145. Mikics E, Toth M, Varju P, Gereben B, Liposits Z, Ashaber M, et al. Lasting changes in social behavior and amygdala function following traumatic experience induced by a single series of footshocks. Psychoneuroendocrinology 2008; 33: 1198-210.
146. Wotjak CT, Landgraf R, Engelmann M. Listening to neuropeptides by microdialysis: Echoes and new sounds? Pharmacol Biochem Behav 2008; 90: 125-34.
147. Berton O, Covington HE, 3rd, Ebner K, Tsankova NM, Carle TL, Ulery P, et al. Induction of deltaFosB in the periaqueductal gray by stress promotes active coping responses. Neuron 2007; 55: 289-300.
148. Sakanaka M, Shiosaka S, Takatsuki K, Inagaki S, Hara Y, Kawai Y, et al. Origins of substance P-containing fibers in the lateral septal area of young rats: Immunohistochemical analysis of experimental manipulations. J Comp Neurol 1982; 212: 268-77.
149. Szeidemann Z, Jakab RL, Shanabrough M, Leranth C. Extrinsic and intrinsic substance P innervation of the rat lateral septal area calbindin cells. Neuroscience 1995; 69: 1205-21.
150. Rosen A, Brodin K, Eneroth P, Brodin E. Short-term restraint stress and s.c. saline injection alter the tissue levels of substance P and cholecystokinin in the peri-aqueductal grey and limbic regions of rat brain. Acta Physiol Scand 1992; 146: 341-8.
151. Pacak K, Palkovits M. Stressor specificity of central neuroendocrine responses: Implications for stress-related disorders. Endocr Rev 2001; 22: 502-48.
152. Simon MJ, Zafra MA, Molina F, Puerto A. Consistent rewarding or aversive effects of the electrical stimulation of the lateral parabrachial complex. Behav Brain Res 2008; 190: 67-73.
153. Jhamandas JH, Petrov T, Harris KH, Vu T, Krukoff TL. Parabrachial nucleus projection to the amygdala in the rat: Electrophysiological and anatomical observations. Brain Res Bull 1996; 39: 115-26.
154. Larsen PJ, Mikkelsen JD. Functional identification of central afferent projections conveying information of acute "stress" to the hypothalamic paraventricular nucleus. J Neurosci 1995; 15: 2609-27.
155. Block CH, Hoffman G, Kapp BS. Peptide-containing pathways from the parabrachial complex to the central nucleus of the amygdala. Peptides 1989; 10: 465-71.
156. Mantyh PW, Hunt SP. Neuropeptides are present in projection neurones at all levels in visceral and taste pathways: From periphery to sensory cortex. Brain Res 1984; 299: 297-312.
157. Yamano M, Hillyard CJ, Girgis S, MacIntyre I, Emson PC, Tohyama M. Presence of a substance P-like immunoreactive neurone system from the parabrachial area to the central amygdaloid nucleus of the rat with reference to coexistence with calcitonin generelated peptide. Brain Res 1988; 451: 179-88.
158. Husum H, Vasquez PA, Mathe AA. Changed concentrations of tachykinins and neuropeptide Y in brain of a rat model of depression: Lithium treatment normalizes tachykinins. Neuropsychopharmacology 2001; 24: 183-91.
159. Husum H, Wortwein G, Andersson W, Bolwig TG, Mathe AA. Gene-environment interaction affects substance P and neurokinin A in the entorhinal cortex and periaqueductal grey in a genetic animal model of depression: implications for the pathophysiology of depression. Int J Neuropsychopharmacol 2008; 11: 93-101.
160. Landgraf R, Wigger A. High vs low anxiety-related behavior rats: An animal model of extremes in trait anxiety. Behav Genet 2002; 32: 301-14.
161. Sartori SB, Ebner K, Muigg P, Landgraf R, Singewald N. Differences in substance P neurotransmission between rats with high vs. low trait anxiety/depression. J Neurochem 2005; 94: 229.
162. Geracioti TD, Jr., Carpenter LL, Owens MJ, Baker DG, Ekhator NN, Horn PS, et al. Elevated cerebrospinal fluid substance p concentrations in posttraumatic stress disorder and major depression. Am J Psychiatry 2006; 163: 637-43.
163. Heikkila L, Rimon R, Terenius L. Dynorphin A and substance P in the cerebrospinal fluid of schizophrenic patients. Psychiatry Res 1990; 34: 229-36.
164. Rimon R, Le Greves P, Nyberg F, Heikkila L, Salmela L, Terenius L. Elevation of substance P-like peptides in the CSF of psychiatric patients. Biol Psychiatry 1984; 19: 509-16.
165. McLean S. Do substance P and the NK1 receptor have a role in depression and anxiety? Curr Pharm Des 2005; 11: 1529-47.
166. Stratton SC, Beresford IJ, Elliott PJ, Hagan RM. Behavioural effects of centrally infused tachykinin NK2 receptor agonists and antagonists in rat models of anxiety. J Psychopharmacol 1993; 7.
167. Teixeira RM, Santos AR, Ribeiro SJ, Calixto JB, Rae GA, De Lima TC. Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice. Eur J Pharmacol 1996; 311: 7-14.
168. Emonds-Alt X. In: Holzer P Ed, Tachykinin NK2 receptor antagonists. Berlin-Heidelberg: Springer 2004; pp. 219-44.
169. Mills SG. In: Bristol JA Ed, Recent advances in neurokinin receptor antagonists. New York:, Academic Press 1997; pp. 51-61.
170. Griebel G, Perrault G, Soubrie P. Effects of SR48968, a selective non-peptide NK2 receptor antagonist on emotional processes in rodents. Psychopharmacology 2001; 158: 241-51.
171. Micale V, Tamburella A, Leggio GM, Mazzola C, Li Volsi V, Drago F. Behavioral effects of saredutant, a tachykinin NK2 receptor antagonist, in experimental models of mood disorders under basal and stress-related conditions. Pharmacol Biochem Behav 2008; 90: 463-9.
172. Ribeiro RL, De Lima TC. Participation of GABAA receptors in the modulation of experimental anxiety by tachykinin agonists and
173. Louis C, Stemmelin J, Boulay D, Bergis O, Cohen C, Griebel G. Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models. Pharmacol Biochem Behav 2008; 89: 36-45.
174. Salomé N, Stemmelin J, Cohen C, Griebel G. Selective blockade of NK2 or NK3 receptors produces anxiolytic- and antidepressant-like effects in gerbils. Pharmacol Biochem Behav 2006; 83: 533-9.
175. Stratton SC, Beresford IJ, Harvey FJ, Turpin MP, Hagan RM, Tyers MB. Anxiolytic activity of tachykinin NK2 receptor antagonists in the mouse light-dark box. Eur J Pharmacol 1993; 250: R11-2.
176. Walsh DM, Stratton SC, Harvey FJ, Beresford IJ, Hagan RM. The anxiolytic-like activity of GR159897, a non-peptide NK2 receptor antagonist, in rodent and primate models of anxiety. Psychopharmacology 1995; 121: 186-91.
177. Griebel G, Moindrot N, Aliaga C, Simiand J, Soubrie P. Characterization of the profile of neurokinin-2 and neurotensin receptor antagonists in the mouse defense test battery. Neurosci Biobehav Rev 2001; 25: 619-26.
178. Dableh LJ, Yashpal K, Rochford J, Henry JL. Antidepressant-like effects of neurokinin receptor antagonists in the forced swim test in the rat. Eur J Pharmacol 2005; 507: 99-105.
179. Stratton SC, Beresford IJ, Hagan RM. GR159897, a potent nonpeptide tachykinin NK2 receptor antagonist, releases suppressed behaviours in a novel aversive environment. Br J Pharmacol 1994; 112: 49P.
180. Sundqvist M, Kristensson E, Adolfsson R, Leffler A, Ahlstedt I, Engberg S, et al. Senktide-induced gerbil foot tapping behaviour is blocked by selective tachykinin NK1 and NK3 receptor antagonists. Eur J Pharmacol 2007; 577: 78-86.
181. Duarte FS, Testolin R, De Lima TC. Further evidence on the anxiogenic-like effect of substance P evaluated in the elevated plusmaze in rats. Behav Brain Res 2004; 154: 501-10.
182. Ikeda K, Miyata K, Orita A, Kubota H, Yamada T, Tomioka K. RP67580, a neurokinin1 receptor antagonist, decreased restraint stress-induced defecation in rat. Neurosci Lett 1995; 198: 103-6.
183. Massi M, Panocka I, de Caro G. The psychopharmacology of tachykinin NK-3 receptors in laboratory animals. Peptides 2000; 21: 1597-609.
184. Panocka I, Massi M, Lapo I, Swiderski T, Kowalczyk M, Sadowski B. Antidepressant-type effect of the NK3 tachykinin receptor agonist aminosenktide in mouse lines differing in endogenous opioid system activity. Peptides 2001; 22: 1037-42.
185. Ribeiro SJ, De Lima TC. Naloxone-induced changes in tachykinin NK3 receptor modulation of experimental anxiety in mice. Neurosci Lett 1998; 258: 155-8.
186. Ribeiro SJ, Teixeira RM, Calixto JB, De Lima TC. Tachykinin NK3receptor involvement in anxiety. Neuropeptides 1999; 33: 181-8.
187. Siuciak JA, McCarthy SA, Martin AN, Chapin DS, Stock J, Nadeau DM, et al. Disruption of the neurokinin-3 receptor (NK3) in mice leads to cognitive deficits. Psychopharmacology 2007; 194: 185-95.
188. Graham AS, Turpin MP, Stubbs CM. Characterisation of the tachykinin-induced hindlimb thumping response in gerbils Neuropeptides 1993; 24: 228-229.
189. Faulhaber HD, Oehme P, Baumann R, Enderlein J, Rathsack R, Rostock G, et al. Substance P in human essential hypertension. J Cardiovasc Pharmacol 1987; 10(Suppl 12): S172-6.
190. Weiss DW, Hirt R, Tarcic N, Berzon Y, Ben-Zur H, Breznitz S, et al. Studies in psychoneuroimmunology: Psychological, immunological, and neuroendocrinological parameters in Israeli civilians during and after a period of Scud missile attacks. Behav Med 1996; 22: 5-14.
191. Schedlowski M, Fluge T, Richter S, Tewes U, Schmidt RE, Wagner TO. Beta-endorphin, but not substance-P, is increased by acute stress in humans. Psychoneuroendocrinology 1995; 20: 103-10.
192. Fehder WP, Sachs J, Uvaydova M, Douglas SD. Substance P as an immune modulator of anxiety. Neuroimmunomodulation 1997; 4: 42-8.
193. Kirschbaum C, Pirke KM, Hellhammer DH. The 'Trier Social Stress Test' - a tool for investigating psychobiological stress responses in a laboratory setting. Neuropsychobiology 1993; 28: 76-81.
194. Rohleder N, Wolf JM, Herpfer I, Fiebich BL, Kirschbaum C, Lieb K. No response of plasma substance P, but delayed increase of interleukin-1 receptor antagonist to acute psychosocial stress. Life Sci 2006; 78: 3082-9.
195. Ermisch A, Ruhle HJ, Landgraf R, Hess J. Blood-brain barrier and peptides. J Cereb Blood Flow Metab 1985; 5: 350-7.
196. Landgraf R, Klauschenz E, Bienert M, Ermisch A, Oehme P. Some observations indicating a low brain uptake of [3H]Nle11-Substance P. Pharmazie 1983; 38: 108-10.
197. Herpfer I, Katzev M, Feige B, Fiebich BL, Voderholzer U, Lieb K. Effects of substance P on memory and mood in healthy male subjects. Hum Psychopharmacol 2007; 22: 567-73.
198. Lieb K, Ahlvers K, Dancker K, Strohbusch S, Reincke M, Feige B, et al. Effects of the neuropeptide substance P on sleep, mood, and neuroendocrine measures in healthy young men. Neuropsychopharmacology 2002; 27: 1041-9.
199. Freed AL, Audus KL, Lunte SM. Investigation of substance P transport across the blood-brain barrier. Peptides 2002; 23: 157-65.
200. Bondy B, Baghai TC, Minov C, Schule C, Schwarz MJ, Zwanzger P, et al. Substance P serum levels are increased in major depression: preliminary results. Biol Psychiatry 2003; 53: 538-42.
201. Cizza G, Marques AH, Eskandari F, Christie IC, Torvik S, Silverman MN, et al. Elevated Neuroimmune Biomarkers in Sweat Patches and Plasma of Premenopausal Women with Major Depressive Disorder in Remission: The POWER Study. Biol Psychiatry 2008; 64: 907-11.
202. Hartman JM, Berger A, Baker K, Bolle J, Handel D, Mannes A, et al. Quality of life and pain in premenopausal women with major depressive disorder: The POWER Study. Health Qual Life Outcomes 2006; 4: 2.
203. Olsson A, Regnell G, Traskman-Bendz L, Ekman R, Westrin A. Cerebrospinal neuropeptide Y and substance P in suicide attempters during long-term antidepressant treatment. Eur Neuropsychopharmacol 2004; 14: 479-85.
204. Russell IJ. The promise of substance P inhibitors in fibromyalgia. Rheum Dis Clin North Am 2002; 28: 329-42.
205. Almay BG, Johansson F, Von Knorring L, Le Greves P, Terenius L. Substance P in CSF of patients with chronic pain syndromes. Pain 1988; 33: 3-9.
206. Lieb K, Walden J, Grunze H, Fiebich BL, Berger M, Normann C. Serum levels of substance P and response to antidepressant pharmacotherapy. Pharmacopsychiatry 2004; 37: 238-9.
207. Maes M, Goossens F, Scharpe S, Meltzer HY, D'Hondt P, Cosyns P. Lower serum prolyl endopeptidase enzyme activity in major depression: Further evidence that peptidases play a role in the pathophysiology of depression. Biol Psychiatry 1994; 35: 545-52.
208. Berrettini WH, Rubinow DR, Nurnberger JI, Jr., Simmons-Alling S, Post RM, Gershon ES. CSF substance P immunoreactivity in affective disorders. Biol Psychiatry 1985; 20: 965-70.
209. Deuschle M, Sander P, Herpfer I, Fiebich BL, Heuser I, Lieb K. Substance P in serum and cerebrospinal fluid of depressed patients: No effect of antidepressant treatment. Psychiatry Res 2005; 136: 1-6.
210. Martensson B, Nyberg S, Toresson G, Brodin E, Bertilsson L. Fluoxetine treatment of depression. Clinical effects, drug concentrations and monoamine metabolites and N-terminally extended substance P in cerebrospinal fluid. Acta Psychiatr Scand 1989; 79: 586-96.
211. Carpenter LL, Bayat L, Moreno F, Kling MA, Price LH, Tyrka AR, et al. Decreased cerebrospinal fluid concentrations of substance P in treatment-resistant depression and lack of alteration after acute adjunct vagus nerve stimulation therapy. Psychiatry Res 2008; 157: 123-9.
212. Carletti R, Corsi M, Melotto S, Caberlotto L. Down-regulation of amygdala preprotachykinin A mRNA but not 3H-SP receptor binding sites in subjects affected by mood disorders and schizophrenia. Eur J Neurosci 2005; 21: 1712-8.
213. Stockmeier CA, Shi X, Konick L, Overholser JC, Jurjus G, Meltzer HY, et al. Neurokinin-1 receptors are decreased in major depressive disorder. Neuroreport 2002; 13: 1223-7.
214. Burnet PW, Harrison PJ. Substance P (NK1) receptors in the cingulate cortex in unipolar and bipolar mood disorder and schizophrenia. Biol Psychiatry 2000; 47: 80-3.
215. Gittins R, Burnet P, Sartori S, Sharp T, Harrison PJ. Neurokinin-1 receptors in the cingulate cortex: Autoradiographic studies in mood disorder and in response to antidepressant drugs. FENS Abstr 2002; 1: A122.12.
216. Michelgard A, Appel L, Pissiota A, Frans O, Langstrom B, Bergstrom M, et al. Symptom provocation in specific phobia affects the substance P neurokinin-1 receptor system. Biol Psychiatry 2007; 61: 1002-6.
217. Fujimura Y, Yasuno F, Farris A, Liow JS, Geraci M, Drevets W, et al. Decreased Neurokinin-1 (Substance P) Receptor Binding in Patients with Panic Disorder: Positron Emission Tomographic Study with [18F]SPA-RQ. Biol Psychiatry 2009 (in press).
218. NCT00102102. www.ClinicalTrials.gov 2008.
219. Kaiya H, Tamura Y, Adachi S, Moriuchi I, Namba M, Tanaka M, et al. Substance P-like immunoreactivity in plasma of psychotic patients and effects of neuroleptics and electroconvulsive therapy. Psychiatry Res 1981; 5: 11-21.
220. Miller C, Kirchmair R, Troger J, Saria A, Fleischhacker WW, Fischer-Colbrie R, et al. CSF of neuroleptic-naive first-episode schizophrenic patients: Levels of biogenic amines, substance P, and peptides derived from chromogranin A (GE-25) and secretogranin II (secretoneurin). Biol Psychiatry 1996; 39: 911-8.
221. Kleinman JE, Hong J, Iadarola M, Govoni S, Gillin CJ. Neuropeptides in human brain - postmortem studies. Prog Neuropsychopharmacol Biol Psychiatry 1985; 9: 91-5.
222. Roberts GW, Ferrier IN, Lee Y, Crow TJ, Johnstone EC, Owens DG, et al. Peptides, the limbic lobe and schizophrenia. Brain Res 1983; 288: 199-211.
223. Iadarola MJ, Ofri D, Kleinman JE. Enkephalin, dynorphin and substance P in postmortem substantia nigra from normals and schizophrenic patients. Life Sci 1991; 48: 1919-30.
224. Zech M, Bogerts B. Methionine-enkephalin and substance P in the basal ganglia of normals, Parkinson patients, Huntington patients, and schizophrenics. A qualitative immunohistochemical study. Acta Neuropathol 1985; 68: 32-8.
225. Toru M, Watanabe S, Shibuya H, Nishikawa T, Noda K, Mitsushio H, et al. Neurotransmitters, receptors and neuropeptides in post-mortem brains of chronic schizophrenic patients. Acta Psychiatr Scand 1988; 78: 121-37.
226. Carruthers B, Dawbarn D, de Quidt M, Emson PC, Hunter J, Reynolds GP. Changes in neuropeptide content of amygdala in schizophrenia. Br J Pharmacol Proc 1984; (Suppl 81): 190P.
227. Nagamine T. Serum substance P levels in patients with chronic schizophrenia treated with typical or atypical antipsychotics. Neuropsychiatr Dis Treat 2008; 4: 289-94.
228. Harrington KA, Augood SJ, Faull RL, McKenna PJ, Emson PC. Dopamine D1 receptor, D2 receptor, proenkephalin A and substance P gene expression in the caudate nucleus of control and schizophrenic tissue: A quantitative cellular in situ hybridisation study. Brain Res Mol Brain Res 1995; 33: 333-42.
229. Rioux L, Nissanov J, Joyce JN. Increased number of [125I] BH-substance P receptors in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 1998; 22: 1295-1299.
230. Weidenhofer J, Yip J, Zavitsanou K, Huang XF, Chahl LA, Tooney PA. Immunohistochemical localisation of the NK1 receptor in the human amygdala: Preliminary investigation in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1313-21.
231. Chappell P. Effects of CP-122,721, a selective NK-1 receptor antagonist, in patients with MDD. Presented at NCDEU June 12 2002.
232. Kramer MS, Winokur A, Kelsey J, Preskorn SH, Rothschild AJ, Snavely D, et al. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology 2004; 29: 385-92.
233. Rupniak NM, Kramer MS. Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists. Trends Pharmacol Sci 1999; 20: 485-90.
234. Kramer M. Clinical Update: Substance P antagonists in patients with major depression. Assoc Eur Psychiatry 2002.
235. Keller M, Montgomery S, Ball W, Morrison M, Snavely D, Liu G, et al. Lack of Efficacy of the Substance P (Neurokinin-1 Receptor) Antagonist Aprepitant in the Treatment of Major Depressive Disorder. Biol Psychiatry 2006; 59: 216-23.
236. NCT00250601. www.ClinicalTrials.gov 2008.
237. NCT00250614. www.ClinicalTrials.gov 2008.
238. NCT00250627. www.ClinicalTrials.gov 2008.
239. NCT00250653. www.ClinicalTrials.gov 2008.
240. NCT00256113. www.ClinicalTrials.gov 2008.
241. NCT00336713. www.ClinicalTrials.gov 2008.
242. NCT00415142. www.ClinicalTrials.gov 2008.
243. Sanofi-Aventis. Information Meeting. http://en.sanofi-aventis.com 2008.
244. NCT00629551. www.ClinicalTrials.gov 2008.
245. NCT00531622. www.ClinicalTrials.gov 2008.
246. Cluzel M. www.gsk.com 2003.
247. Furmark T, Appel L, Michelgard A, Wahlstedt K, Ahs F, Zancan S, et al. Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol Psychiatry 2005; 58: 132-42.
248. Davis M. Functional neuroanatomy of anxiety and fear: A focus on the amygdala. Neurobiology of mental illness 1999: 463-474.
249. Aggleton J. The Amygdala: A Functional Analysis. Oxford-New York: Oxford University Press 2000.
250. NCT00383786. www.ClinicalTrials.gov 2008.
251. NCT00403962. www.ClinicalTrials.gov 2008.
252. Nagle M. In www.DrugResearcher.com, 2008.
253. GSK. Product Development Pipeline. www.gsk.com 2008.
254. NCT00511654. www.ClinicalTrials.gov 2008.
255. NCT00675116. www.ClinicalTrials.gov 2008.
256. NCT00273039. www.ClinicalTrials.gov 2008.
257. NCT00390533. www.ClinicalTrials.gov 2008.
258. NCT00390650. www.ClinicalTrials.gov 2008.
259. Kronenberg G, Berger P, Tauber RF, Bandelow B, Henkel V, Heuser I. Randomized, double-blind study of SR142801 (Osanetant). A novel neurokinin-3 (NK3) receptor antagonist in panic disorder with pre- and posttreatment cholecystokinin tetrapeptide (CCK-4) challenges. Pharmacopsychiatry 2005; 38: 24-9.
260. Meltzer HY, Arvanitis L, Bauer D, Rein W. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry 2004; 161: 975-84.
261. NCT00049946. www.ClinicalTrials.gov 2008.
262. NCT00103727. www.ClinicalTrials.gov 2008.
263. NCT00300963. www.ClinicalTrials.gov 2008.
264. Evangelista S. Talnetant GlaxoSmithKline. Curr Opin Investig Drugs 2005; 6: 717-21.
265. Meltzer H, Prus A. NK3 receptor antagonists for the treatment of schizophrenia. Drug Discov Today Ther Strat 2006; 3: 555-60.
266. Smith PW, Dawson LA. Neurokinin 3 (NK3) receptor modulators for the treatment of psychiatric disorders. Recent Patents CNS Drug Discov 2008; 3: 1-15.
267. NCT00102492. www.ClinicalTrials.gov 2008.
268. NCT00413023. www.ClinicalTrials.gov 2008.
269. Takeda. Takeda Annual Report 2003. www.takeda.com 2003.
270. Roche. www.roche.com 2004.
271. Roche. Full Year results 2005. www.roche.com 2006.
272. Millan MJ. Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 2006; 110: 135-370.
273. Nemeroff CB. Advancing the treatment of mood and anxiety disorders: The first 10 years' experience with paroxetine. Psychopharmacol Bull 2003; 37(Suppl 1): 6-7.
274. Millan MJ. The neurobiology and control of anxious states. Prog Neurobiol 2003; 70: 83-244.
275. Mathew SJ, Manji HK, Charney DS. Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology 2008; 33: 2080-92.
276. Mathew SJ, Price RB, Charney DS. Recent advances in the neurobiology of anxiety disorders: Implications for novel therapeutics. Am J Med Genet C Semin Med Genet 2008; 148: 89-98.
277. Thase ME, Rush AJ. When at first you don't succeed: Sequential strategies for antidepressant nonresponders. J Clin Psychiatry 1997; 58(Suppl 13): 23-9.
278. Ryckmans T, Balancon L, Berton O, Genicot C, Lamberty Y, Lallemand B, et al. First dual NK1 antagonists-serotonin reuptake inhibitors: synthesis and SAR of a new class of potential antidepressants. Bioorg Med Chem Lett 2002; 12: 261-4.
279. Ryckmans T, Berton O, Grimee R, Kogej T, Lamberty Y, Pasau P, et al. Dual NK1 antagonists - serotonin reuptake inhibitors as potential antidepressants. Part 2: SAR and activity of benzyloxyphenethyl piperazine derivatives. Bioorg Med Chem Lett 2002; 12: 3195-8.
280. Gobert A, Brocco M, Dekeyne A, Di Cara B, Bouchez G, Lejeune F, et al. Neurokinin-1 antagonists potentiate antidepressant properties of serotonin reuptake inhibitors, yet blunt their anxiogenic actions: A neurochemical, electrophysiological, and behavioral characterization. Neuropsychopharmacology 2009; (in press).
281. 1A autoreceptor adaptive changes in substance P (neurokinin 1) receptor knock-out mice mimic antidepressant-induced desensitization. J Neurosci 2001; 21: 8188-97
282. 1A autoreceptors in mice. J Neurochem 2005; 95: 1713-23.
283. Haddjeri N, Blier P. Sustained blockade of neurokinin-1 receptors enhances serotonin neurotransmission. Biol Psychiatry 2001; 50: 191-9
284. Lieb K, Fiebich BL, Herpfer I, Mantovani M, Loffler M, Feuerstein TJ. No modulatory effect of neurokinin-1 receptor antagonists on serotonin uptake in human and rat brain synaptosomes. Eur Neuropsychopharmacol 2005; 15: 641-6.
285. Blier P, Gobbi G, Haddjeri N, Santarelli L, Mathew G, Hen R. Impact of substance P receptor antagonism on the serotonin and norepinephrine systems: Relevance to the antidepressant/anxiolytic response. J Psychiatry Neurosci 2004; 29: 208-18.
286. Guiard BP, Guilloux JP, Reperant C, Hunt SP, Toth M, Gardier AM. Substance P neurokinin 1 receptor activation within the dorsal raphe nucleus controls serotonin release in the mouse frontal cortex. Mol Pharmacol 2007; 72: 1411-8.
287. Chenu F, Guiard BP, Bourin M, Gardier AM. Antidepressant-like activity of selective serotonin reuptake inhibitors combined with a NK1 receptor antagonist in the mouse forced swimming test. Behav Brain Res 2006; 172: 256-63.
288. Liu R, Ding Y, Aghajanian GK. Neurokinins activate local glutamatergic inputs to serotonergic neurons of the dorsal raphe nucleus. Neuropsychopharmacology 2002; 27: 329-40.
289. Valentino RJ, Bey V, Pernar L, Commons KG. Substance P Acts through local circuits within the rat dorsal raphe nucleus to alter serotonergic neuronal activity. J Neurosci 2003; 23: 7155-9.
290. Maubach KA, Martin K, Chicchi G, Harrison T, Wheeldon A, Swain CJ, et al. Chronic substance P (NK1) receptor antagonist and conventional antidepressant treatment increases burst firing of monoamine neurones in the locus coeruleus. Neuroscience 2002; 109: 609-17.
291. Duman RS. Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromolecular Med 2004; 5: 11-25.
292. Morcuende S, Gadd CA, Peters M, Moss A, Harris EA, Sheasby A, et al. Increased neurogenesis and brain-derived neurotrophic factor in neurokinin-1 receptor gene knockout mice. Eur J Neurosci 2003; 18: 1828-36.
293. Czeh B, Fuchs E, Simon M. NK1 receptor antagonists under investigation for the treatment of affective disorders. Expert Opin Investig Drugs 2006; 15: 479-86.
294. Czeh B, Pudovkina O, van der Hart MG, Simon M, Heilbronner U, Michaelis T, et al. Examining SLV-323, a novel NK1 receptor antagonist, in a chronic psychosocial stress model for depression. Psychopharmacology 2005; 180: 548-57.
295. van der Hart MG, Czeh B, de Biurrun G, Michaelis T, Watanabe T, Natt O, et al. Substance P receptor antagonist and clomipramine prevent stress-induced alterations in cerebral metabolites, cytogenesis in the dentate gyrus and hippocampal volume. Mol Psychiatry 2002; 7: 933-41.
296. Malberg JE, Schechter LE. Increasing hippocampal neurogenesis: A novel mechanism for antidepressant drugs. Curr Pharm Des 2005; 11: 145-55
297. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003; 301: 805-9.
298. Bilkei-Gorzo A, Racz I, Michel K, Zimmer A. Diminished anxiety-and depression-related behaviors in mice with selective deletion of the Tac1 gene. J Neurosci 2002; 22: 10046-52.
299. Zocchi A, Varnier G, Arban R, Griffante C, Zanetti L, Bettelini L, et al. Effects of antidepressant drugs and GR 205171, an neurokinin-1 (NK1) receptor antagonist, on the response in the forced swim test and on monoamine extracellular levels in the frontal cortex of the mouse. Neurosci Lett 2003; 345: 73-6.
300. Brocco M, Dekeyne A, Mannoury la Cour C, Touzard M, Girardon S, Veiga S, et al. Cellular and behavioural profile of the novel, selective neurokinin1 receptor antagonist, vestipitant: A comparison to other agents. Eur Neuropsychopharmacol 2008; 18: 729-50.
301. Singewald N. Altered brain activity processing in high-anxiety rodents revealed by challenge paradigms and functional mapping. Neurosci Biobehav Rev 2007; 31: 18-40.
302. Muigg P, Sartori SB, Sparber T, Landgraf R, Singewald N. Reduced depression-like behaviour in HAB rats after NK1-receptor antagonist treatment is associated with an altered neuronal activation pattern in specific brain areas. Abstract at the Meeting of the Austrian Neuroscience Association 2005.
303. Borsini F, Podhorna J, Marazziti D. Do animal models of anxiety predict anxiolytic-like effects of antidepressants? Psychopharmacology 2002; 163: 121-41.
304. Griebel G. 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: More than 30 years of research. Pharmacol Ther 1995; 65: 319-95.
305. Pohl R, Yeragani VK, Balon R, Lycaki H. The jitteriness syndrome in panic disorder patients treated with antidepressants. J Clin Psychiatry 1988; 49: 100-4.
306. Spigset O. Adverse reactions of selective serotonin reuptake inhibitors: reports from a spontaneous reporting system. Drug Saf 1999; 20: 277-87.
307. Campbell BM, Merchant KM. Serotonin 2C receptors within the basolateral amygdala induce acute fear-like responses in an openfield environment. Brain Res 2003; 993: 1-9.
308. 2C receptors. Neuropharmacology 2000; 39: 1114-7.
309. Salchner P, Singewald N. 5-HT receptor subtypes involved in the anxiogenic-like action and associated Fos response of acute fluoxetine treatment in rats. Psychopharmacology 2006; 185: 282-8.
310. Apfel CC, Malhotra A, Leslie JB. The role of neurokinin-1 receptor antagonists for the management of postoperative nausea and vomiting. Curr Opin Anaesthesiol 2008; 21: 427-32.
311. Madsen JL, Fuglsang S. A randomized, placebo-controlled, crossover, double-blind trial of the NK1 receptor antagonist aprepitant on gastrointestinal motor function in healthy humans. Aliment Pharmacol Ther 2008; 27: 609-15.
312. Holzer P, Holzer-Petsche U. Tachykinins in the gut. Part I. Expression, release and motor function. Pharmacol Ther 1997; 73: 173-217.
313. Da Settimo F, Taliani S, Trincavelli ML, Montali M, Martini C. GABA A/Bz receptor subtypes as targets for selective drugs. Curr Med Chem 2007; 14: 2680-701.
314. Abi-Dargham A, Moore H. Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia. Neuroscientist 2003; 9: 404-16.
315. Schechter LE, Ring RH, Beyer CE, Hughes ZA, Khawaja X, Malberg JE, et al. Innovative approaches for the development of antidepressant drugs: Current and future strategies. NeuroRx 2005; 2: 590-611.
316. Harro J. CCK and NPY as anti-anxiety treatment targets: Promises, pitfalls, and strategies. Amino Acids 2006; 31: 215-30.
317. Chaki S, Okubo T, Sekiguchi Y. Non-monoamine-based approach for the treatment of depression and anxiety disorders. Recent Patents CNS Drug Discov 2006; 1: 1-27.
318. Gasparini F, Bilbe G, Gomez-Mancilla B, Spooren W. mGluR5 antagonists: discovery, characterization and drug development. Curr Opin Drug Discov Devel 2008; 11: 655-65.
319. Holsboer F, Ising M. Central CRH system in depression and anxiety - evidence from clinical studies with CRH1 receptor antagonists. Eur J Pharmacol 2008; 583: 350-7.
320. Karlsson RM, Holmes A. Galanin as a modulator of anxiety and depression and a therapeutic target for affective disease. Amino Acids 2006; 31: 231-9.
321. Ong J, Kerr DI. Clinical potential of GABAB receptor modulators. CNS Drug Rev 2005; 11: 317-34.
322. Holmes A, Heilig M, Rupniak NM, Steckler T, Griebel G. Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol Sci 2003; 24: 580-8.
323. Morinobu S, Strausbaugh H, Terwilliger R, Duman RS. Regulation of c-Fos and NGF1-A by antidepressant treatments. Synapse 1997; 25: 313-20.
324. Andreae LC, Herbert J. Expression of c-fos in restricted areas of the basal forebrain and brainstem following single or combined intraventricular infusions of vasopressin and corticotropin-releasing factor. Neuroscience 1993; 53: 735-48.
325. Hahn MK, Bannon MJ. Tachykinin NK1 receptor antagonists enhance stress-induced c-fos in rat locus coeruleus. Eur J Pharmacol 1998; 348: 155-60.
326. Haley GE, Flynn FW. Blockade of NK3R signaling in the PVN decreases vasopressin and oxytocin release and c-Fos expression in the magnocellular neurons in response to hypotension. Am J Physiol Regul Integr Comp Physiol 2008; 295: R1158-67.
327. Hetzenauer A, Corti C, Herdy S, Corsi M, Ferraguti F, Singewald N. Individual contribution of metabotropic glutamate receptor (mGlu) 2 and 3 to c-Fos expression pattern evoked by mGlu2/3 antagonism. Psychopharmacology 2008; 201: 1-13.
328. Linden AM, Bergeron M, Schoepp DD. Comparison of c-Fos induction in the brain by the mGlu2/3 receptor antagonist LY341495 and agonist LY354740: evidence for widespread endogenous tone at brain mGlu2/3 receptors in vivo. Neuropharmacology 2005; 49 Suppl 1: 120-34.
329. Nguyen NK, Keck ME, Hetzenauer A, Thoeringer CK, Wurst W, Deussing JM, et al. Conditional CRF receptor 1 knockout mice show altered neuronal activation pattern to mild anxiogenic challenge. Psychopharmacology 2006; 188: 374-85.
330. Pietersen CY, Bosker FJ, Postema F, Fokkema DS, Korf J, den Boer JA. Ketamine administration disturbs behavioural and distributed neural correlates of fear conditioning in the rat. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1209-18.
331. Wersinger SR, Ginns EI, O'Carroll AM, Lolait SJ, Young WS, 3rd. Vasopressin V1b receptor knockout reduces aggressive behavior in male mice. Mol Psychiatry 2002; 7: 975-84.
332. Nguyen NK, Sartori SB, Herzog H, Tasan R, Sperk G, Singewald N. Effect of neuropeptide Y Y2 receptor deletion on emotional stress-induced neuronal activation in mice. Synapse 2008; 63: 236-46.
333. Guiard BP, Przybylski C, Guilloux JP, Seif I, Froger N, De Felipe C, et al. Blockade of substance P (neurokinin 1) receptors enhances extracellular serotonin when combined with a selective serotonin reuptake inhibitor: An in vivo microdialysis study in mice. J Neurochem 2004; 89: 54-63.
334. Corcoran BM, Stanton C, Fitzgerald G, Ross RP. Life under stress: The probiotic stress response and how it may be manipulated. Curr Pharm Des 2008; 14(14): 1382-99.
335. Starowicz K, Cristino L, Di Marzo V. TRPV1 receptors in the central nervous system: Potential for previously unforeseen therapeutic applications. Curr Pharm Des 2008; 14(1): 42-54.
336. Syed R, Au K, Cahill C, Duggan L, He Y, Udu V, Xia J. Pharmacological interventions for clozapine-induced hypersalivation. Cochrane Database Syst Rev 2008; (3): CD005579.